Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1004 in NSCLC
NCT06046495Phase 1Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd. Primary endpoint: Safety profile of PLB1004 per CTCAE v5.0 up to 2 years. Started Jul 2024; status: recruiting.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06046495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046495.